论文部分内容阅读
20例结核病人(组1)体外(E-玫瑰花,以下简称为“E”)和体内(2,4-二硝基氯苯,以下简称为“D”)细胞免疫试验,“E”为50.3±4.2%,“D”为25%(20例健康的泰国人“E”为77.1%,“D”为80%)。所有20例组1的病人以惯用剂量的异烟肼,乙胺丁醇治疗18个月。另一组15例结核病人(组2)以异烟肼、乙胺丁醇外加每日150mg 每周2次的左旋咪唑治疗8个月。组1在治疗3个月时,“E”为58.3%,9个月为69.7%;组2治疗3个月时“E”为71.2%,9个月为84.7%。尽管组2的治
E-rose (hereinafter referred to as “E”) and in vivo (2,4-dinitrochlorobenzene, hereinafter abbreviated as “D”) cell immunity test were performed on 20 patients with tuberculosis (Group 1) 50.3 ± 4.2% and “D” was 25% (20% healthy Thai “E” was 77.1%, “D” was 80%). All 20 patients in Group 1 were treated with isoniazid, ethambutol at the usual dose for 18 months. Another group of 15 tuberculosis patients (Group 2) was treated with isoniazid, ethambutol plus levamisole 150 mg twice daily twice daily for 8 months. At 3 months of treatment, group E had a mean of 58.3% for E and 69.7% for 9 months. Group E had 71.2% for 3 months and 84.7% for 9 months. Despite the treatment of group 2